2. Others
  3. Drug Derivative
  4. (+)-Decanoylcarnitine

(+)-Decanoylcarnitine is an (S)-acylcarnitine derivative and a potent inhibitor of carnitine-acylcarnitine translocase, with an IC50 of 5 μM. (+)-Decanoylcarnitine acts as a competitive inhibitor of long-chain acylcarnitine transferase and (-)-carnitine palmityltransferase. (+)-Decanoylcarnitine blocks hepatic fatty acid oxidation, ketogenesis, oleate-induced activation of gluconeogenesis, as well as associated changes in acetyl-CoA, citrate, redox pair ratios, flavins and pyridine nucleotides. (+)-Decanoylcarnitine reverses ketosis in vivo, enhances insulin-mediated hypoglycemic effects in anesthetized animals, and reduces plasma ketone body levels when used in combination with insulin. (+)-Decanoylcarnitine can be used in studies related to diabetic ketoacidosis.

For research use only. We do not sell to patients.

(+)-Decanoylcarnitine

(+)-Decanoylcarnitine Chemical Structure

CAS No. : 25518-51-8

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of (+)-Decanoylcarnitine:

(+)-Decanoylcarnitine Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

(+)-Decanoylcarnitine is an (S)-acylcarnitine derivative and a potent inhibitor of carnitine-acylcarnitine translocase, with an IC50 of 5 μM. (+)-Decanoylcarnitine acts as a competitive inhibitor of long-chain acylcarnitine transferase and (-)-carnitine palmityltransferase. (+)-Decanoylcarnitine blocks hepatic fatty acid oxidation, ketogenesis, oleate-induced activation of gluconeogenesis, as well as associated changes in acetyl-CoA, citrate, redox pair ratios, flavins and pyridine nucleotides. (+)-Decanoylcarnitine reverses ketosis in vivo, enhances insulin-mediated hypoglycemic effects in anesthetized animals, and reduces plasma ketone body levels when used in combination with insulin. (+)-Decanoylcarnitine can be used in studies related to diabetic ketoacidosis[1][2][3].

In Vitro

(+)-Decanoylcarnitine (compound 11b) belongs to (S)-acylcarnitine derivatives, and acts as a potent inhibitor of carnitine-acylcarnitine translocase with an IC50 value of 5 μM[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

(+)-Decanoylcarnitine Related Antibodies
In Vivo

(+)-Decanoylcarnitine (administered intravenously at a concentration of 20 mg/mL, infused at a rate of 75 μl/min for the first 10 min, followed by continuous infusion at 10 μl/min until 2 h) reduces plasma ketone body levels by 1240 μmol/100 mL within 4 hours in alloxan-diabetic anesthetized rats with ketoacidosis[1].
(+)-Decanoylcarnitine (20 mg/mL; intravenous injection; infused over 10 min) reduces plasma ketone body levels by 609 μmol/100 mL within 2 hours in conscious alloxan-diabetic rats with ketoacidosis[1].
(+)-Decanoylcarnitine (20 mg/mL; intravenous injection; single injection duration of 2 min) reduces plasma ketone bodies more rapidly than insulin alone in unanesthetized, non-intubated alloxan-diabetic rats with ketoacidosis when used alone[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague-Dawley (male, initial weight ~130 g, weight ~100 g at experiment start, alloxan-induced diabetic ketoacidosis)[1]
Dosage: 20 mg/mL
Administration: i.v.; 75 μl/min for 10 min then 10 μl/min until 2 h
Result: Reduced plasma ketone levels from an initial 1,502 μmol/100 mL to 262 μmol/100 mL over 4 hours.
When combined with insulin, reduced plasma ketones from an initial 1,532 μmol/100 mL to 69 μmol/100 mL over 4 hours.
Had no effect on plasma glucose, with levels remaining at ~1,043-1,045 mg/100 mL over 4 hours.
When combined with insulin, reduced plasma glucose from an initial 896 mg/100 mL to 281 mg/100 mL over 4 hours.
Animal Model: Sprague-Dawley (male, initial weight ~130 g, weight ~100 g at experiment start, alloxan-induced diabetic ketoacidosis)[1]
Dosage: 20 mg/mL
Administration: i.v.; 10 min infusion
Result: Reduced plasma ketone levels from an initial 1,863 μmol/100 mL to 1,254 μmol/100 mL over 2 hours.
When combined with insulin, reduced plasma ketones from an initial 1,754 μmol/100 mL to 717 μmol/100 mL over 2 hours.
Had no effect on plasma glucose, and did not enhance insulin-induced hypoglycemia in awake animals.
Caused an increase in plasma free fatty acid levels, and blunted the insulin-induced fall in free fatty acids.
Animal Model: Sprague-Dawley (male, initial weight ~130 g, weight ~100 g at experiment start, alloxan-induced diabetic ketoacidosis)[1]
Dosage: 20 mg/mL (0.5 mL total)
Administration: i.v.; single injection over 2 min
Result: Reduced plasma ketone levels at a faster rate than insulin alone.
The combination of (+)-Decanoylcarnitine and insulin produced a greater ketone reduction than either agent alone.
Had no effect on plasma glucose, and did not enhance insulin-induced hypoglycemia.
Did not blunt the insulin-induced fall in free fatty acids.
Molecular Weight

315.45

Formula

C17H33NO4
CAS No.
SMILES

[C@@H](OC(CCCCCCCCC)=O)(C[N+](C)(C)C)CC([O-])=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

(+)-Decanoylcarnitine Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

(+)-Decanoylcarnitine25518-51-8Drug DerivativeDrug derivativehepatic fatty acid oxidationdiabetic ketoacidosisalloxan-diabetic ratscitrategluconeogenesisacetyl CoAlong-chain acylcarnitine transferaseketogenesiscarnitine palmityltransferasepyridine nucleotideInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
(+)-Decanoylcarnitine
Cat. No.:
HY-165175
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.